NCT00568074View on ClinicalTrials.gov

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

December 16, 2003

Primary Completion Date

September 2, 2004

Study Completion Date

September 2, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

DRUG

Glurenorm®

DRUG

Glucobay®

Trial Locations (4)

100029

Novo Nordisk Investigational Site, Beijing

200025

Novo Nordisk Investigational Site, Shanghai

200433

Novo Nordisk Investigational Site, Shanghai

610041

Novo Nordisk Investigational Site, Chengdu

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00568074 - Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter